LY-2940094

LY-2940094

LY-2940094

LY-2940094 is a potent and selective nociceptin receptor antagonist which is under investigation by Eli Lilly for the treatment of major depressive disorder and alcohol dependence.[1][2] As of 2014, it is in phase II clinical trials for both of the aforementioned indications.[1][2] Its chemical structure has yet to be published.[1]

See also

References

  1. ^ a b c Dale, Elena; Bang-Andersen, Benny; Sánchez, Connie (2015). "Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs" (PDF). Biochemical Pharmacology 95 (2): 81–97.  
  2. ^ a b Yin, Xin; Guven, Nuri; Dietis, Nikolas (2015). "Opioids in Depression: Not Quite There Yet" (PDF). UK Journal of Pharmaceutical and Biosciences 3 (1): 12–17. 

External links

  • LY-2940094 - AdisInsight